Physician profile
David A Dasher
NPI 1821210337
$2,568.08
in general payments reported to CMS, 2019-2025
18 companies · $595 in 2025
The $595 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $653 · 2020: $89.95 · 2021: $11.31 · 2022: $287 · 2023: $556 · 2024: $375 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,416 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,415.72 |
| Education | $110.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $519.05 | 2019-2025 | Rinvoq |
| Sun Pharmaceutical Industries INC. | $477.27 | 2019-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $402.74 | 2019-2025 | |
| Janssen Biotech, INC. | $208.62 | 2019-2023 | Tremfya |
| Pfizer INC. | $194.22 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $172.76 | 2022-2025 | Sotyktu |
| Merz North America, INC. | $160.53 | 2019 | |
| Leo Pharma INC. | $81.83 | 2023-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $77.14 | 2023-2024 | Vtama |
| Ucb, INC. | $62.68 | 2019-2020 | |
| Revance Therapeutics, INC. | $58.74 | 2024 | Daxxify |
| Galderma Laboratories, L.P. | $41.05 | 2025 | Nemluvio |
| Genentech USA, INC. | $31.06 | 2019-2023 | Erivedge |
| Organon LLC | $19.41 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $18.37 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.53 | 2019 | |
| Genzyme Corporation | $14.21 | 2022 | |
| Lilly USA, LLC | $13.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dasher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.